1. Pazopanib (Votrient®) Medical Review, FDA 22–465, October 2009.
2. Votrient® (pazopanib) Prescribing Information, GSK June 2014.
3. Votrient® (pazopanib) Assessment Report, EMEA WC500094275, June 2010.
4. Votrient® (pazopanib) Assessment Report, EMEA WC5000131044, May 2012.
5. Votrient® (pazopanib) EPAR, Product Characteristics. EMEA WC500094272, February 2015.